Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), its partner for the Comirnaty COVID-19 vaccine, made legal submissions to London's Court of Appeal on Thursday seeking to overturn a prior court ruling ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a ...

Pfizer quoted this statement in its countersuit, highlighted that Moderna has made “more than $30 billion from COVID-19 vaccine sales” since the start of the pandemic — Pfizer is projected ...

The 2nd U.S. Circuit Court of Appeals ruled in favor of Pfizer (PFE), in a lawsuit by Do No Harm challenging the company's diversity fellowship program. Read more here.

Pfizer and the direct purchasers entered into the settlement agreement Nov. 22. The agreement still needs official court approval. More articles on legal & regulatory issues: ...

The court held that DNH lacked legal standing and dismissed the challenge to Pfizer’s diversity program. The Second Circuit’s decision creates a potential roadblock for challenges levied by ...

Neither Pfizer nor its outside lawyers from Dechert and Paul, Weiss, Rifkind, Wharton & Garrison responded to my email query on the amicus filings. The company has until April 8 to respond to the ...

But it's the Pfizer case that seems to me to be a more important harbinger of the challenges companies may face as they try to encourage diversity and inclusion in the workplace.

Appeals court rejects challenge to Pfizer’s diverse fellowship pipeline ... Legal scrutiny of DEI initiatives has become increasingly popular in recent months.Texas Gov. Greg Abbott banned such ...

Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read more here.